Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LA. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 2012;60(2):321–7.
Article
CAS
PubMed
Google Scholar
Joosten LA, Heinhuis B, Netea MG, Dinarello CA. Novel insights into the biology of interleukin-32. Cell Mol Life Sci. 2013;70(20):3883–92.
Article
CAS
PubMed
Google Scholar
Khawar MB, Abbasi MH, Sheikh N. IL-32: a novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediat Inflamm. 2016;2016:8413768.
Article
Google Scholar
Wang S, Chen F, Tang L. IL-32 promotes breast cancer cell growth and invasiveness. Oncol Lett. 2015;9(1):305–7.
Article
PubMed
Google Scholar
Wang Y, Yang Y, Zhu Y, Li L, Chen F, Zhang L. Polymorphisms and expression of IL-32: impact on genetic susceptibility and clinical outcome of lung cancer. Biomarkers. 2017;22(2):165–70.
Article
CAS
PubMed
Google Scholar
Yang Y, Wang Z, Zhou Y, Wang X, Xiang J, Chen Z. Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J Surg Oncol. 2015;13:146.
Article
PubMed
PubMed Central
Google Scholar
Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES, et al. IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene. 2011;30(30):3345–59.
Article
CAS
PubMed
PubMed Central
Google Scholar
Park ES, Yoo JM, Yoo HS, Yoon DY, Yun YP, Hong J. IL-32gamma enhances TNF-alpha-induced cell death in colon cancer. Mol Carcinog. 2014;53(Suppl 1):E23–35.
Article
CAS
PubMed
Google Scholar
Yun HM, Park KR, Kim EC, Han SB, Yoon DY, Hong JT. IL-32alpha suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget. 2015;6(11):9061–72.
Article
PubMed
PubMed Central
Google Scholar
Nishida A, Andoh A, Inatomi O, Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem. 2009;284(26):17868–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Plantinga TS, Costantini I, Heinhuis B, Huijbers A, Semango G, Kusters B, et al. A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma. Carcinogenesis. 2013;34(7):1529–35.
Article
CAS
PubMed
Google Scholar
Heinhuis B, Plantinga TS, Semango G, Kusters B, Netea MG, Dinarello CA, et al. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis. 2016;37(2):197–205.
Article
CAS
PubMed
Google Scholar
Gorvel L, Korenfeld D, Tung T, Klechevsky E. Dendritic cell-derived IL-32alpha: a novel inhibitory cytokine of NK cell function. J Immunol. 2017;199(4):1290–300.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cheon S, Lee JH, Park S, Bang SI, Lee WJ, Yoon DY, et al. Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. J Biol Chem. 2011;286(14):12049–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Park MH, Song MJ, Cho MC, Moon DC, Yoon DY, Han SB, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2012;135(1):63–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22(1):131–42.
CAS
PubMed
Google Scholar
Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther. 2006;8(6):R166.
Article
PubMed
PubMed Central
Google Scholar
Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS ONE. 2008;3(4):e1985.
Article
PubMed
PubMed Central
Google Scholar
Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA. 2008;105(9):3515–20.
Article
CAS
PubMed
Google Scholar
Ohmatsu H, Humme D, Gonzalez J, Gulati N, Mobs M, Sterry W, et al. IL-32 induces indoleamine 2,3-dioxygenase(+)CD1c(+) dendritic cells and indoleamine 2,3-dioxygenase(+)CD163(+) macrophages: relevance to mycosis fungoides progression. Oncoimmunology. 2017;6(2):e1181237.
Article
PubMed
Google Scholar
Suga H, Sugaya M, Miyagaki T, Kawaguchi M, Fujita H, Asano Y, et al. The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134(5):1428–35.
Article
CAS
PubMed
Google Scholar
Lee J, Kim KE, Cheon S, Song JH, Houh Y, Kim TS, et al. Interleukin-32alpha induces migration of human melanoma cells through downregulation of E-cadherin. Oncotarget. 2016;7(40):65825–36.
PubMed
PubMed Central
Google Scholar
Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4(7):816–27.
Article
CAS
PubMed
PubMed Central
Google Scholar
Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.
Article
PubMed
PubMed Central
Google Scholar
Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33(5):890–904.
Article
CAS
PubMed
Google Scholar
Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412–6.
Article
CAS
PubMed
Google Scholar
Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteom. 2005;4(12):1920–32.
Article
CAS
Google Scholar
Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:6352.
Article
Google Scholar
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
Article
PubMed
Google Scholar
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
Article
PubMed
PubMed Central
Google Scholar
Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 2018;8(8):935–43.
Article
CAS
PubMed
Google Scholar
Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 2007;130(1):77–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang T, Cooper S, Brockdorff N. The interplay of histone modifications—writers that read. EMBO Rep. 2015;16(11):1467–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet. 2011;12(1):7–18.
Article
PubMed
Google Scholar
Soares LM, He PC, Chun Y, Suh H, Kim T, Buratowski S. Determinants of histone H3K4 methylation patterns. Mol Cell. 2017;68(4):773–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Qin Y, Milton DR, Oba J, Ding Z, Lizee G, Ekmekcioglu S, et al. Inflammatory IL-1beta-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res. 2015;28(2):236–9.
Article
CAS
PubMed
Google Scholar
Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA. Interleukin 32 (IL-32) contains a typical alpha-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 2012;287(8):5733–43.
Article
CAS
PubMed
Google Scholar
Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA. 2006;103(9):3316–21.
Article
CAS
PubMed
Google Scholar
Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, et al. Identification of the most active interleukin-32 isoform. Immunology. 2009;126(4):535–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bai X, Shang S, Henao-Tamayo M, Basaraba RJ, Ovrutsky AR, Matsuda JL, et al. Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2015;112(16):5111–6.
Article
CAS
PubMed
Google Scholar
Kim SJ, Lee S, Kwak A, Kim E, Jo S, Bae S, et al. Interleukin-32gamma transgenic mice resist LPS-mediated septic shock. J Microbiol Biotechnol. 2014;24(8):1133–42.
Article
CAS
PubMed
Google Scholar
Qu Y, Taylor JL, Bose A, Storkus WJ. Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther. 2011;18(9):663–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation. Eur J Med Res. 2015;20:7.
Article
PubMed
PubMed Central
Google Scholar
Kim MS, Kang JW, Jeon JS, Kim JK, Kim JW, Hong J, et al. IL-32theta gene expression in acute myeloid leukemia suppresses TNF-alpha production. Oncotarget. 2015;6(38):40747–61.
Article
PubMed
PubMed Central
Google Scholar
Kang JW, Park YS, Lee DH, Kim JH, Kim MS, Bak Y, et al. Intracellular interaction of interleukin (IL)-32alpha with protein kinase Cepsilon (PKCepsilon) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells. J Biol Chem. 2012;287(42):35556–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dos Santos JC, Heinhuis B, Gomes RS, Damen MS, Real F, Mortara RA, et al. Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species. PLoS Negl Trop Dis. 2017;11(2):e0005413.
Article
PubMed
PubMed Central
Google Scholar
Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RM, Vaidya P, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med. 2014;6(250):250ra114.
Article
PubMed
PubMed Central
Google Scholar
Schenk M, Krutzik SR, Sieling PA, Lee DJ, Teles RM, Ochoa MT, et al. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med. 2012;18(4):555–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou Y, Zhu Y. Important role of the IL-32 inflammatory network in the host response against viral infection. Viruses. 2015;7(6):3116–29.
Article
CAS
PubMed
PubMed Central
Google Scholar
Palstra RJ, de Crignis E, Roling MD, van Staveren T, Kan TW, van Ijcken W, et al. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1. Sci Adv. 2018;4(2):e1701729.
Article
PubMed
PubMed Central
Google Scholar
Nicholl MB, Chen X, Qin C, Bai Q, Zhu Z, Davis MR, et al. IL-32alpha has differential effects on proliferation and apoptosis of human melanoma cell lines. J Surg Oncol. 2016;113(4):364–9.
Article
CAS
PubMed
Google Scholar
Yun HM, Oh JH, Shim JH, Ban JO, Park KR, Kim JH, et al. Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals. Cell Death Dis. 2013;4:e640.
Article
CAS
PubMed
PubMed Central
Google Scholar
Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten LA. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci USA. 2011;108(12):4962–7.
Article
CAS
PubMed
Google Scholar
Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci. 2015;72(7):1249–60.
Article
CAS
PubMed
Google Scholar
Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Iida M, et al. Molecular network associated with MITF in skin melanoma development and progression. J Skin Cancer. 2011;2011:730170.
Article
PubMed
PubMed Central
Google Scholar
Hsiao JJ, Fisher DE. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys. 2014;563:28–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ahmed F, Haass NK. Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance. Front Oncol. 2018;8:173.
Article
PubMed
PubMed Central
Google Scholar
Kobayashi H, Lin PC. Molecular characterization of IL-32 in human endothelial cells. Cytokine. 2009;46(3):351–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn). 2018;22(1A):61–7.
PubMed
PubMed Central
Google Scholar